Smart Pill Bottle receives the Good Design Award 2016
Personal medical device leveraging "Internet of Things" technologies to address medication adherence.
Intelligent Product Solutions (IPS) and AdhereTech have announced that the Smart Pill Bottle received the prestigious Good Design Award 2016. The Good Design award is the world's oldest prize dedicated to the most innovative and cutting-edge industrial products and graphic designs produced around the world.
For the 2016 edition of the Good Design award, the jury evaluated more than 900 candidates from 46 countries, with products spanning a range of sectors, from electronics to robotics, from furnishing to graphics and vehicles.
The AdhereTech Smart Pill Bottle, designed by IPS and AdhereTech, is a personal medical device leveraging "Internet of Things" technologies to address a major problem in the healthcare sector - medication adherence. With the high cost of medication and the health risks of straying from a dosage schedule, patient adherence is paramount to successful care. The AdhereTech Smart Pill Bottle is currently used by leading pharmaceutical companies and pharmacies across the globe.
"We are thrilled that the AdhereTech Smart Pill Bottle was recognized by the Good Design award for its excellence in design, and are very proud of our design work on it," said Mitch Maiman, cofounder and President of IPS. "At IPS, we pride ourselves on our best-in-class design and development of products, and this award further validates our leadership in design."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.